Biogen Inc. has reached an agreement to acquire Apellis Pharmaceuticals, Inc. for approximately $5.6 billion. The biotechnology company announced the deal on Tuesday, confirming that the transaction will be conducted entirely in cash.

Biogen announced on Tuesday that it has agreed to acquire Apellis Pharmaceuticals for 5.6 billion dollars. The all-cash deal was confirmed by the company.
Biogen Inc. has reached an agreement to acquire Apellis Pharmaceuticals, Inc. for approximately $5.6 billion. The biotechnology company announced the deal on Tuesday, confirming that the transaction will be conducted entirely in cash.

網頁上的所有功能,更快,隨手可用。